A Conversation about Navigating Health Benefit Costs and GLP-1 Dilemmas

[00:00:00] Imagine getting this massive 26% raise over a five-year period. Which sounds amazing, right? Exactly. You're feeling great. You're finally getting ahead. Only to realize that almost every single penny of that raise, and honestly sometimes even more than that, was secretly intercepted. Mm-hmm. Just drained away before it ever reached your bank account. Right. And the scary part is that's not some, you know, dystopian thought experiment. That is literally what is happening to the American worker right now. It really is. It's the reality we're living in.

[00:00:29] So today we are diving into that classic autumn ritual of open enrollment, but we're looking at it through a lens that explains why you probably feel this creeping sense of dread every time you open that dense jargon-filled benefits packet. Oh, the cognitive fatigue is so real. You sit down at your desk, you skim those premium tables, and you notice your paycheck deduction has ticked up yet again. Yep. Every single year. And usually, out of sheer overwhelm, you just click whatever plan you had last year.

[00:00:57] All right. Just so you can get back to your actual job. But clicking that box this year carries a completely different kind of weight. I mean, we are recording this just a day after the Kaiser Family Foundation, the KFF, released their 28th annual employer health benefits survey for 2026. And the numbers they released are genuinely staggering. They really are.

[00:01:18] We are looking at a situation where the employer-sponsored health insurance system, which is, you know, the fundamental safety net for nearly 157 million Americans under the age of 65. It's just buckling. It's at a breaking point. Exactly. So our mission for this deep dive is to really tear into a comprehensive new review that was published just this month in the Human Capital Leadership Review. Right. By Jonathan H. Westover. Yes. And the title honestly says it all. It's called The Benefits Breaking Point. Okay. Let's unpack this because we need to establish the stakes here.

[00:01:48] Yeah. And the health economics community is treating this moment as a literal breaking point. Right. The conventional levers that corporate leaders have pulled for the last, oh, three decades to absorb these rising medical costs, they are simply tapped out. There's no more slack in the rope. None. And we have to be clear immediately, this isn't just some peripheral finance issue or, you know, an actuarial puzzle for human resources to quietly solve in a spreadsheet. Right. It's bigger than that.

[00:02:15] It is a fundamental crisis of organizational justice because health benefits are the most tangible, most direct signal an organization sends to you about whether or not they value your well-being. Yeah, that makes total sense. When leadership treats the annual health plan renewal purely as a budgetary nuisance, they cause this profound, sometimes irreparable damage to the psychological contract they have with their workforce.

[00:02:38] I want to take that personal feeling, that specific stress you feel sitting at your desk during open enrollment and connect it directly to the macro data that validates it. Let's do it. Because if you're wondering why your wallet feels noticeably lighter this year, the math is incredibly clear. Let's look at these 2026 KFF numbers. The sticker shock is real. It is.

[00:03:00] Right now, the average worker with family coverage is contributing $7,471 a year out of their paycheck just toward their premium. Which is a massive 9% jump from 2025. 9%. In one year. And we really have to remember that the $7,000 is only the employee's localized pain point. Right. That's just what comes out of the check. Exactly.

[00:03:22] When you zoom out and look at the total family premium, meaning the amount you pay out of pocket, plus the massive subsidy your employer pays on your behalf, that total number has reached $28,303 for 2026. $28,000. Tied to a single employee's health plan. It's unbelievable. You could buy a very decent used car for that. I mean, in some markets, that's a down payment on a home. It's an astronomical amount of capital.

[00:03:49] And that five-year trend line reveals the stealth wealth destruction you mentioned at the very start. The 26% raise thing? Right. Over the last five years, family premiums have risen 28%. Now, if we map that against wage growth, which sat at 26.9%, and inflation, which was 24.4% over the same window, a very grim picture emerges. So you look at your pay stub, you see a nominal raise, and you feel this brief moment of success. But it's an illusion.

[00:04:17] Yeah, because if your health care premiums are outrunning your wage growth, your compensation is essentially vaporizing in real time. The purchasing power is gone before you even have a chance to budget it. But the truly alarming part of Westover's analysis is how unevenly this burden is distributed. It's not hitting everyone the same way. Not at all. This isn't a shared sacrifice across the American economy.

[00:04:39] If you work at a small firm, which the data defines as an organization with 10 to 199 employees, you are contributing an average of $9,687 a year for family coverage. Wow. Now, compare that to your peers at large firms who are contributing about $6,840. Let me just process that. The smaller the company you work for, the more punitive your health care costs are.

[00:05:06] You are paying nearly $10,000 just in premiums to work at a mid-sized business. The penalty for working at a small firm is severe. The KFF data shows that nearly a third, 31% of covered workers at these small firms who need family coverage are contributing $12,000 or more a year. A thousand bucks a month. Just vanishing from take-home pay for the privilege of carrying the insurance card. And the craziest part is that card doesn't even mean your care is paid for.

[00:05:36] I mean, we haven't even touched the deductibles yet. Right. Because the deductible is the cash you have to hand over to a doctor or a hospital out of your own pocket before the insurance company pays a single dime. Right. And I'm guessing the small firm penalty applies there, too. The pattern of inequity remains identical. The average deductible for single coverage across the board is about $1,900. But at a small firm, it averages over $2,600. That is rough.

[00:06:03] And there are massive geographical disparities, too. A family premium in the Northeast is averaging over $31,000, while the South is sitting around $26,000. So if I'm an employee at like a small graphic design firm or a local manufacturing plant, I might be paying $12,000 a year out of my paycheck. Plus, I have a $2,600 deductible hanging over my head if I actually get sick. Exactly.

[00:06:29] It genuinely feels like you're being forced to buy a reliable used car every single autumn before you are even permitted to see a primary care doctor. That's a painfully accurate way to put it. I mean, if I'm out of pocket $15,000 before the insurance even starts working for me, the concept of employer-sponsored insurance feels like a complete illusion. Like, what exactly are they sponsoring? That exact question is echoing through break rooms and HR departments nationwide right now.

[00:06:58] And to understand the mechanics of how we arrived here, we really need to differentiate between two concepts. Cost sharing and cost shifting. Okay. Break that down for us. So cost sharing is the traditional historical model. That's where the employer and employee equitably split the total cost of the premium based on a predetermined ratio. Like an 80-20 split or something. Right. But what we are witnessing today is aggressive, systematic cost shifting.

[00:07:27] This is a deliberate strategy by employers to move a larger and larger share of the raw cost away from the corporate ledger and directly onto the employee's shoulders. Usually massed through those higher deductibles or higher paycheck contributions we just talked about. Exactly. And the Westover paper points out that this kind of flat dollar cost shifting is inherently regressive, doesn't it? Like it punishes the people who can least afford it. Oh, absolutely. Think about the internal math of a corporation.

[00:07:56] If a company gets a massive renewal increase and decides to pass along by raising every employee's premium contribution by $1,000 a year, the optics might look fair on paper. Because technically everyone pays $1,000. Right. But $1,000 is a devastating percentage of a frontline warehouse worker's take-home pay. For the vice president of operations, that same $1,000 is just a rounding error. It barely registers.

[00:08:21] When organizations rely on flat dollar cost shifting, the financial burden falls disproportionately, almost violently, on the lowest earners. Unless the organization has the foresight to deliberately design their benefits to prevent it. Okay. So if a small business employee is suddenly paying 9% more this year, they are looking around the hospital room wondering what exactly they are funding. Naturally. Because our hospital gowns are not suddenly made of silk, right? The bandages are the exact same. The waiting rooms honestly feel more crowded.

[00:08:51] So who is cashing that massive markup? Where is this tsunami of money actually going? To trace the money, we have to look at the forward projections. Preliminary data from Marsh's 2026 National Survey, which polled over 1,800 employers, projects that total health benefit costs per employee will rise by 8.2% in 2027. 8.2%. Which represents the highest single year increase since 2003.

[00:09:17] And the most terrifying part of that 8.2% figure in the Westover paper is that it represents the projected increase after employers implement all their planned cost reduction measures. Right. That's the mitigated number. So if they just sat back and did absolutely nothing, what would the true inflation rate be? The raw, unmitigated increase would be 11%. 11%. Yep. That is completely unsustainable. Employers are already planning to pull every emergency lever they have just to artificially suppress the inflation down to that 8.2%.

[00:09:48] The business group on health released a concurrent survey projecting a 9.2% trend before plan changes. The economic consensus is absolute. A massive surge is already baked into the system. So let's follow the money. Who are the primary drivers of this surge? The first and arguably most structural driver is hospital consolidation and the resulting pricing power. Okay. Hospitals buying up other hospitals. Exactly.

[00:10:13] In that business group on health survey, 62% of large employers explicitly pointed to hospital price increases as a primary engine of their cost crisis. Cumulatively, employer costs for hospital services have skyrocketed a projected 76% from 2018 through 2027. Wait. 76% in less than a decade? Yes. That makes no sense. I go to the grocery store, the price of an apple is the price of an apple.

[00:10:38] Why do hospital systems have so much leverage to continually hike prices on corporate America without any pushback? It really comes down to localized market monopolies. Over the last decade, large hospital systems have systematically acquired independent hospitals and bought up private physician practices in specific geographic regions. So they just corner the market. When they consolidate an entire region, they become the only game in town.

[00:11:03] An employer has to offer a health insurance network that includes the dominant local hospital system. If they don't, the insurance is functionally useless to their employees who live there. Right. You can't tell your employees, hey, your network is great, but the nearest hospital is three hours away. Exactly. And the hospital executives know this, which grants them immense pricing power in the commercial market. But doesn't Medicare control costs better? Medicare uses statutory formulas, literal laws, to dictate exactly what they will pay a hospital.

[00:11:33] Commercial employers don't have that legislative shield, so they end up paying negotiated rates that are massive multiples of the public Medicare rates. But if the employer is theoretically buying bulk health care for thousands of people, shouldn't they have some volume leverage? Why are they weaker than the government? Because corporate America is heavily fragmented. Even a Fortune 500 employer only represents a fraction of a regional hospital's total patient base.

[00:11:58] And this vulnerability is massively compounded by the actual funding structure of large employer plans. Okay, this is where we need to talk about being self-funded, right? Yes. We need to define what it means to be self-funded. Because the paper notes that 71% of covered workers are in self-funded plans. And that actually jumps to 85% at large firms. Which surprises a lot of people. Yeah, break down the mechanics of self-funding for the listener. Because I think most people fundamentally misunderstand who is actually paying their doctor.

[00:12:28] The vast majority of employees assume that when they hand over a Blue Cross or an Aetna card at the doctor's office, that massive insurance company is paying their medical bills. That's what I always assumed. For large employers, that assumption is entirely false. Being self-funded means the employer pays the medical claims directly out of their own corporate treasury. Wait, literally out of the company bank account? Literally. They simply hire the insurance company to act as a third-party administrator,

[00:12:55] essentially a very expensive paperwork processor that rents out its network of doctors. So the insurance company takes zero financial risk. The employer holds all the risk. If someone gets sick, the cash comes straight out of the company's operating budget. Precisely. Which brings us to the second and third major cost drivers, pharmacy and high-cost catastrophic claims. Let's talk pharmacy because that's huge. Pharmacy now consumes roughly 25% of total health spending for large employers.

[00:13:24] And this isn't being driven by, you know, generic antibiotics or generic blood pressure pills. Right. We're not talking about amoxicillin here. The crisis is in specialty drugs. Medications for cancer, autoimmune conditions, and rare diseases. Cancer currently ranks as a top three cost condition for 92% of large employers. And because these companies are acting as their own insurance company, a single catastrophic claim can be financially devastating.

[00:13:50] I know the paper specifically mentions new cell and gene therapies that cost hundreds of thousands, sometimes millions of dollars. A single employee, or even a dependent of an employee, requiring a rare disease gene therapy that costs $2 million, can completely annihilate a mid-sized self-funded company's entire annual health care budget in one afternoon. One afternoon. That is terrifying for a CFO. Because they do not have a massive national insurance risk pool to absorb that financial shock.

[00:14:19] They are absorbing it directly against their bottom line. Okay. So we have hospital monopolies artificially dictating regional prices, and we have the constant threat of unpredictable $2 million gene therapies. But we have to talk about the massive elephant in the pharmacy right now. Yes, we do. There is one specific class of drugs uniquely straining the American corporate system, and it demands its own highly nuanced discussion because everyone is talking about it. The GLP-1 weight loss drugs.

[00:14:47] The GLP-1 dilemma is, without question, the most complex, politically charged, and financially daunting challenge benefit leaders face today. Let's define them first. Sure. GLP-1 receptor agonists are a class of medications that mimic a gut hormone deeply involved in appetite and blood sugar regulation. They were initially developed and approved for type 2 diabetes management. But several of them, specifically semaglutide, which is branded as WGOV,

[00:15:15] and tirzepatide, branded as Zepbound, are now FDA-approved for chronic weight management. And to call them effective is almost an insult to the data, right? The clinical results are practically miraculous for people who have struggled for decades. They really are. The Westover paper cites the pivotal clinical trials, the Wilding study and the Gestriboff study. These trials demonstrated mean weight loss of 15 to 21 percent over roughly a year and a half.

[00:15:42] That level of efficacy is historically unprecedented. Right. When you compare that to a 2 percent weight loss on a placebo, this is a life-altering medical intervention for someone battling obesity. The clinical efficacy is staggered. But the landscape entirely shifted with the publication of the SELECT trial. Tell us about the SELECT trial. Well, the medical community realized these drugs were not just about the number on the scale. The SELECT trial tracked semaglutide in adults who were overweight or obese

[00:16:11] and had established cardiovascular disease. But critically, these patients did not have diabetes. Okay. So if they didn't have diabetes, what was the clinical outcome the trial was actually looking for? And what did they find? They were looking at heart health, and they found a 20 percent reduction in major adverse cardiovascular events. Wow. Twenty percent. We are talking about actively preventing heart attacks and strokes. So the conversation instantly evolved.

[00:16:39] We are no longer just discussing a highly effective weight loss tool. We are discussing highly effective preventative cardiovascular medicine. The clinical benefits are profound and undeniable. But those profound clinical benefits come with a price tag. That is inducing panic attacks in HR departments. Panic is the right word. The Marsh survey estimates that GLP-1s account for a full 1 percent of the total 8.2 percent health cost growth projected for 2027. It's hard to overstate how wild that is. Think about that.

[00:17:08] Out of all the hospitals, all the surgeries, all the other drugs in America, just one single class of drugs is driving an eighth of the national health care inflation trend. And we could see the localized devastation of this trend in the data. The paper site's Jefferson Health, which is a major health system that also operates an insurance division. The chief executive of that division reported a staggering loss of roughly $180 million

[00:17:34] and attributed roughly a third of that massive deficit solely to skyrocketing spending on GLP-1s. Almost $60 million just on one type of drug. So when companies face a deficit like that, how do they react? A massive portion of them are just pulling the plug entirely. Yeah. According to the KFF data, only 18 percent of firms with 200 or more workers currently cover these drugs specifically for weight loss. Just 18 percent. And the fallout from that is immense.

[00:18:01] GoodRx and NPR data cited in the paper estimate that roughly 12 million people lost their insurance coverage for Wagovi and ZepBound between 2025 and 2026. Just gone. Simply because employer plans tighten their belts and drop the benefit. What's fascinating here is the fundamental economic tension. Obesity is a chronic systemic disease with cascading long-term health consequences, right? It leads to orthopedic joint issues, cardiovascular disease, metabolic syndrome. Right. It affects everything.

[00:18:32] So curing or aggressively treating obesity should, in theory, save the healthcare system an absolute fortune over a lifetime. That's the logical conclusion? But the costs of the GLP-1 drug are immediate, often running over $1,000 a month per patient. While the massive cardiovascular savings, like avoiding a $200,000 open heart surgery, accrue over a timeline of 5, 10, or 15 years. Oh, I see where this is going. The actuarial timeline is completely broken.

[00:19:00] It's the employee turnover problem. Exactly. Because of natural employee turnover in the modern economy, the employer who pays the massive immediate upfront cost for the GLP-1 drug today is almost never the same employer who reaps the long-term financial savings of the prevented heart attack a decade from now. Because that employee will have moved on to three different companies by then. Right. It's an actuarial mismatch. The investment yields a negative return for the company funding it. So let me get this straight.

[00:19:28] We finally have a pharmaceutical intervention that practically cures one of the most expensive, debilitating chronic conditions in America. But employers are actively dropping it because it works too well? The demand is unprecedented and the company might not get their return on investment before the employee updates their LinkedIn profile and takes a new job? That's the painful reality. Are we financially punishing employees for seeking a cure to a chronic illness?

[00:19:54] From the perspective of the employee whose prescription is suddenly denied, it absolutely feels like a punitive betrayal. But from the perspective of a cheap financial officer, it feels like an unsolvable math equation. The math just doesn't work. If 30% of your entire workforce qualifies for a $12,000 a year medication and they all decide to take it, your company's health care budget explodes overnight. It could erase the company's entire profit margin for the year.

[00:20:21] Okay, so if employers can't figure out how to afford these miracle drugs and they can't stop the regional hospital monopolies from price gouging, what is their default setting? When they panic, what do they actually do? Their default setting is to hand the bill to you. Westover categorizes this reactive employer response as the trap of cost shifting. Right, the shifting we talked about earlier. The KFF data illustrates the panic perfectly.

[00:20:47] Among large firms surveyed about projected cost increases, 44% responded by raising the premium share that workers pay out of their checks. And 21% simply raised the deductibles or the cost sharing for most medical services. But Westover argues that the strategy is fundamentally flawed, not just morally, but economically. Yes. He cites a foundational piece of health economics research to prove it, the Brat Goldberg study from 2017. What exactly did Brat Goldberg and her team uncover?

[00:21:17] This study dismantled a long-held economic theory. Brat Goldberg and her colleagues analyzed a large self-insured firm that made a radical decision. They forced all of their employees into a high-deductible health plan. Which a lot of companies do. Right. The traditional whiteboard economic theory behind high-deductibles, often called the consumer-driven healthcare movement, posits that if you give employees skin in the game, meaning they have to pay out of pocket first,

[00:21:46] they will magically transform into savvy, rational consumers. That's the theory. They'll shop around. They'll compare MRI prices, demand generic drugs, and drive down overall costs through the invisible hand of the free market. But come on, if people have to pay $2,000 out of pocket before their insurance kicks in, they aren't going to spend a week researching hospital prices. They're just going to sit on the couch and hope the pain goes away. That natural human reaction is exactly what the data bears out.

[00:22:16] Spending fell at the firm, yes. The high-deductible plan reduced costs. But it did not fall because employees became savvy price shoppers. What happened? The researchers found zero evidence that employees shifted toward lower-priced providers or negotiated better rates. Instead, they just completely stopped going to the doctor. Wow. They cut back on care broadly and indiscriminately. They skipped valuable preventative care. They delayed filling essential maintenance prescriptions.

[00:22:44] And they ignored early warning symptoms. Because you don't shop around for a cheaper emergency room when you think you're having an appendix issue. You just panic. Or worse, you ignore the excruciating pain because you can't afford the $2,000 just to walk through the hospital doors and find out what's wrong. Exactly. Here's where it gets really interesting. Raising a deductible to make employees better shoppers is like raising the price of a fire extinguisher to make people better at putting out fires. They don't learn fire safety.

[00:23:13] They just watch the house burn down. That fire extinguisher analogy is perfectly aligned with the clinical data. Because the fire eventually reaches the emergency room. And then it's way more expensive. The clinical impacts of this indiscriminate rationing are devastating. When an employee skips chronic care management or preventive screenings to save a few hundred dollars today, it leads to avoidable vastly more expensive complications, disability, and absenteeism tomorrow. Right.

[00:23:41] Treating a massive stroke in the ICU is infinitely more expensive than paying for a generic blood pressure medication for 20 years. Cost shifting creates a facade of savings while building a mountain of deferred clinical risk. And economically, the employee gets hit twice. We talked earlier about stagnant wages. The Baker and Chandra study from 2006 proved this empirically, didn't they? They did. They demonstrated that rising health premiums directly cause slower wage growth.

[00:24:06] You are literally paying for your company's health care inefficiency through a suppressed salary. You pay for it in suppressed wages. And you pay for it in suppressed career mobility. The paper highlights a devastating phenomenon called job lock, which was thoroughly documented by Bridget Madrian in 1994. Job lock. What is that?

[00:24:27] It's when employees who have complex medical needs or who have spouses or children with complex medical needs remain trapped in jobs they absolutely despise simply to maintain access to a specific insurance network or coverage policy. The idea that a generation of talent might be permanently trapped in cubicles they hate just to keep their family alive, that is bleak. From an organizational behavior standpoint, it is a disaster.

[00:24:52] When a leadership team treats the annual renewal purely as a spreadsheet exercise, shifting costs until the math works, they might hit their budget, but they fail as leaders. Right, because look at who you're retaining. If your primary retention tool is job lock, you aren't retaining top tier innovative talent. You are trapping a deeply resentful, disengaged workforce that will do the bare minimum required to not get fired.

[00:25:17] Okay, so if cost shifting fails clinically because it forces people to skip care and it fails economically because it stifles wages and breeds resentment, what happens when it crosses the line into legal jeopardy? Because this isn't just about bad culture anymore. It's about the law. The legal landscape is shifting with unprecedented speed, and it is becoming incredibly perilous for employers who remain asleep at the wheel. We must discuss ERISA, the Employee Retirement Income Security Act.

[00:25:44] I know this usually comes up with retirement plans. Right. Under ERISA, self-funded employers possess a strict, legally binding fiduciary duty. They are mandated by law to manage their health plans prudently and exclusively in the best interest of the plan participants. To put that in perspective, if your company manages your 401k retirement plan, they can't legally put your money into a terrible mutual fund with exorbitant fees just because it's convenient for them.

[00:26:12] They would be sued for breaching their fiduciary duty. You're saying the exact same legal standard applies to health care funds? The exact same standard. And employees are finally waking up to this and dragging their employers into federal court. Finally. The Westover paper details recent highly publicized lawsuits against corporate giants like Johnson & Johnson and Wells Fargo.

[00:26:33] Former employees launched class action lawsuits alleging that these corporations brazenly breached their fiduciary duties by vastly overpaying for routine generic drugs through their pharmacy benefit managers, or PBMs. Let me make sure I understand the allegation here. The lawsuits claim the companies were blindly handing their corporate credit card to a middleman, letting that middleman gouge them on generic drugs, and then passing those artificially inflated costs directly onto the employees through higher paycheck premiums?

[00:27:03] That is the core of the allegation. Now, it is crucial to note that both of these specific cases were recently dismissed, J&J in December 2025 and Wells Fargo in March 2025. Okay, so they won. Well, they were dismissed on procedural grounds, primarily related to the legal concept of standing. The courts ruled that the specific plaintiffs could not prove direct, individualized, concrete harm in the manner required for that specific legal maneuver. Ah, I see.

[00:27:31] But the legal community is not viewing these dismissals as exonerations. They are viewing them as massive warning shots. The judges did not issue rulings saying these companies were doing a spectacular job managing their plans. They simply ruled on procedural mechanics. It sounds like companies are blindly handing their corporate credit card to a middleman, getting sued for the charges, and then making the employees pay the bill to cover it up. It's a huge mess.

[00:27:55] And not only are they handing over the credit card, but until very recently, it was completely legal for that middleman to hide the receipts. I'm looking at the notes on the Consolidated Appropriations Act of 2020. Well, the system was astonishingly opaque. Prior to the Consolidated Appropriations Act of 2020, PBMs and insurance carriers could legally embed gag clauses in their contracts. Gag clauses? Yes. These clauses quite literally forbade an employer from accessing their own claims data.

[00:28:23] The employer could not see what they were actually paying for specific drugs. That is insane. Imagine a restaurant telling you, you have to pay this $1,000 bill, but it's a breach of contract for you to ask for an itemized receipt to see what you actually ate. It was a deeply flawed, anti-competitive system. The 2020 legislation finally banned those gag clauses, mandating transparency. Good.

[00:28:46] Yet, the KFF survey found that even today, only 49% of large firms report that they actually receive sufficient data on drug pricing and rebates from their PBMs. Wait, only 49%? Half of corporate America is still flying blind, managing millions of dollars in healthcare spend without granular data. If half of these companies don't even fully understand what they are paying for, how does the average employee process the constant cuts and premium hikes? It has to destroy trust.

[00:29:16] It shatters it. And the paper dives deeply into organizational behavior research to explain this phenomenon, specifically examining psychological contract breach, citing Zhao's 2007 meta-analysis, and the concept of organizational justice based on Jason Colquitt's research. Unpack organizational justice for us. What does justice look like in the context of a health insurance portal? This raises an important question about human behavior.

[00:29:42] Organizational justice revolves around the perception of fairness. Yes. Colquitt's research demonstrates that humans do not solely react to the outcome of a situation, for example, the frustrating outcome of having to pay higher premiums. Right. They react with equal, if not greater, intensity to the process.

[00:29:59] If your leadership team transparently explains a massive cost deficit, involves the workforce in analyzing the solutions, and ultimately makes a difficult change, employees might dislike the outcome, but they will generally accept the process as fair. But if an arbitrary change, like suddenly losing coverage for a medication you rely on, just appears in your open enrollment portal with zero explanation or warning? Then it feels like a profound betrayal.

[00:30:24] It fundamentally breaches the psychological contract, the unspoken foundational agreement of mutual respect and reciprocity between employer and employee. And what happens then? When that trust is breached, the data shows that turnover intentions instantly spike, discretionary effort plummets, and a toxic cynicism takes root in the organizational culture. Man.

[00:30:47] We have spent a lot of time outlining a very dark reality today, the astronomical costs, the GLP-1 tension, the clinical failure of cost shifting, and the legal landmines. It's heavy. If I am an HR director or a CFO listening to this, I am probably sweating. But we promised an evidence-based playbook for how leaders can actually navigate out of this mess. Westover provides a structured five-step plan. Let's get into it. Let's do it.

[00:31:13] The first step focuses on how organizations buy their health care, purchasing discipline. Purchasing discipline is about fundamentally changing governance. It demands that organizations stop treating health benefits as an annual administrative chore and start treating it as a rigorous governed procurement function. No more rubber stamping the renewal. Exactly. You cannot accept the initial boilerplate contract from a PPM.

[00:31:38] You must demand full claims data, full rebate transparency, and you must continually audit that data with independent experts. The paper highlights a truly incredible case study to illustrate what happens when someone actually apprised discipline to the system, the Montana State Employee Health Plan. Walk us through the Marilyn Bartlett story because it sounds like a movie. It really does. Marilyn Bartlett is a revered figure in the benefits industry.

[00:32:04] Back in 2014, the Montana State Health Plan covered roughly 30,000 lives and it was in a complete financial death spiral. Just hemorrhaging money. The plan faced a projected $28.9 million deficit and was on a mathematically guaranteed track for total insolvency by 2017. Bartlett, who brought the mindset of a forensic CPA to the role, took over as administrator and treated the entire healthcare system like a massive accounting problem to be solved.

[00:32:33] If she's facing a $28 million deficit, she can't just ask the local hospitals nicely for a 2% discount. She must have completely rewritten the rules of how the state paid its bills. She did. She fundamentally changed the architecture of the payment system by moving the state plan to something called reference-based pricing. How does that work? Let's look at how hospital billing normally works. Typically, a hospital bills an entirely arbitrary, massively inflated chargemaster rate.

[00:33:02] The insurance network then negotiates a supposed discount off that inflated charge. Okay. If a hospital arbitrarily charges $100,000 for a knee surgery that actually costs $10,000 to perform, and the insurance company brags about negotiating a 50% discount, the employer's still paying $50,000. It's a completely fabricated discount. It's the classic department store trick. You mark a generic shirt up to $200 just so you can put a giant 50% off sticker on it,

[00:33:31] and the consumer feels great paying $100 for a $20 shirt. Exactly. And Bartlett refused to play the department store game. Under reference-based pricing, the Montana plan looked at the hospitals and said, We are no longer negotiating discounts off your fictional billed charges. We know exactly what Medicare pays you for these procedures because that is public data. Oh, that's smart. Moving forward, we will pay you a generous multiple of that Medicare rate,

[00:33:57] specifically 2.2 to 2.5 times the Medicare rate, so you can maintain a profit. But we will not pay a penny more. And because she controlled the healthcare access for 30,000 state employees, the hospitals couldn't just walk away. They had to accept reality. They didn't have a choice. The results cited in the paper are unbelievable. They generated $47.8 million in hospital savings. They completely replaced their opaque PBM, resulting in a 23% drop in drug costs.

[00:34:25] By 2017, instead of facing insolvency, Bartlett had built a $112 million reserve fund. It remains the ultimate proof of concept for rigorous purchasing discipline. But it's worth pausing to explain exactly how they achieved that 23% drop in drug costs, because it exposes the core flaw of the PBM industry. Yeah, how did they drop it that much? The traditional PBM business model relies heavily on spread pricing.

[00:34:54] Let's trace a hypothetical pill. A local pharmacy buys a pill for $10. The PBM reimburses that pharmacy $12 for dispensing it. Okay, makes sense. But the PBM turns around and sends an invoice to the employer, billing them $50 for that exact same pill. Wait, what? That $38 difference? The PBM simply pockets it. That is spread pricing. And it creates a massive conflict of interest, where the entity hired to manage your drug costs

[00:35:24] actually profits immensely when drug prices are higher. That is wild. Okay, the Montana story is incredibly inspiring, but I have to push back on the reality of implementing it. Fair enough. Montana succeeded because they brought the weight of an entire state government to the negotiating table. They had 30,000 lives as leverage. If you're a mid-sized software company or a regional manufacturing plant with 500 employees, you can't just walk into the local hospital monopoly and demand reference-based pricing.

[00:35:54] They would laugh you out of the boardroom and tell your employees to go somewhere else. You are hitting on a very real limitation of scale. It is undeniably harder for a 500-person company to unilaterally dictate terms to a hospital monopoly. However, the fundamental principle of fiduciary governance still applies, just scaled differently. So what can a smaller company actually do? A mid-sized company might not be able to force a hospital into reference-based pricing alone,

[00:36:21] but they can immediately demand a transparent pass-through PBM contract where the PBM is paid a flat, predictable administrative fee per employee rather than allowing them to skim rebates and rely on spread pricing. So cut out the hidden fees. Furthermore, mid-sized companies can join regional employer purchasing coalitions. By banding together with 10 other mid-sized companies, they pool their covered lives to create the leverage they lack individually. The overarching key is treating the health plan

[00:36:49] with the exact same relentless scrutiny and independent auditing that a corporate board applies to its 401k retirement committee. Okay, so the first step is cleaning up the supply chain, negotiating better actual prices, and reclaiming ownership of your data. But once you secure a better underlying cost structure, how do you pass that design on to the employee? Right. That transitions us to the second step of the playbook, value-based insurance design, or VBID. Value-based insurance design is a concept championed by researchers

[00:37:19] like Michael Chernew at Harvard back in 2007. The core philosophy is beautifully simple, yet it requires a radical departure from how 99% of insurance plans operate today. How so? VBID dictates that we should determine an employee's cost sharing, their deductibles and co-pays, based entirely on the clinical value of the medical service, not the underlying price of the service. We must stop using blunt instruments that treat all medical interventions as equally necessary.

[00:37:48] If we shouldn't treat all care the same, how does this actually work in the real world? The gold standard example is the post-heart attack trial conducted by Aetna, led by Nitesh Chowdhury and published in 2011. The researchers tracked a cohort of patients who had just survived a myocardial infarction, a heart attack. Standard undisputed medical protocol dictates that these patients must be placed on a strict regimen of evidence-based preventive medications, such as beta blockers and statins,

[00:38:17] to prevent a fatal second heart attack. But under a normal, traditional insurance plan, the patient still has to walk into the pharmacy and pay a $20 or $30 co-pay every single month to get those life-saving pills. Exactly. And what the clinical researchers discovered was that even seemingly trivial co-pays, $10 or $20 a month, were creating enough financial friction that patients were skipping doses, splitting pills, or abandoning their prescriptions entirely. Just to save $20. So, in this trial,

[00:38:46] Aetna radically altered the design. They completely eliminated the co-payments for these specific, highly valuable cardiac medications. They made them 100% free to the patient. Which sounds like terrible business logic for an insurance company trying to save money. But what actually happened? The clinical outcomes were remarkable. Adherence to the medication schedule improved significantly. As a direct result, the patient suffered significantly fewer subsequent major vascular events. Because they actually took their meds.

[00:39:15] And most importantly for the finance department, they achieved these massive health improvements without increasing total overall health spending. It's the ultimate spend money to save money concept. They gave away expensive drugs completely for free, the patients stayed healthier, and the insurance company didn't lose a single dime because they avoided paying for second heart attacks. The upfront cost of providing the medication for free was entirely subsidized by the massive, catastrophic costs they avoided in the emergency room.

[00:39:43] This is the exact inverse of the Brooks-Goldberg high deductible study we dissected earlier. Oh, right, where people just stopped going to the doctor altogether. High deductibles build a massive, indiscriminate wall that blocks people from accessing both useless, wasteful care and vital, life-saving care. Value-based design builds a frictionless, high-speed highway for vital care and strategically places expensive toll booths on the useless care. If the math works so perfectly, why is this so rare?

[00:40:13] Are HR departments just incapable of differentiating between the clinical value of a daily beta blocker and the value of an elective knee surgery? The barrier isn't a lack of desire. It's the anchor of legacy technology. Traditional insurance claims administration systems were built in the 1980s and 90s to process broad, simplistic categories. All specialist visits require a $50 copay or all Tier 2 drugs require a $30 copay. They aren't built for nuance.

[00:40:42] Designing a highly nuanced system that zeroes out cost-sharing for specific drugs but only for specific patients who have specific clinical diagnoses requires immense data integration. It requires a long-term investment mindset rather than a desperate, short-term, cost-cutting mindset. The Westover paper also mentions that a true value-based approach should scale premium contributions based on employee pay bans, right? Yes. If an organization truly values equity

[00:41:11] and organizational justice, they restructure their premium contributions so that a frontline worker making $40,000 a year pays a significantly smaller percentage of the total premium than a vice president making $250,000 a year. Which just makes sense. This actively shields the most vulnerable, lowest-wage workers from the regressive shock of annual healthcare inflation. So a value-based design means removing friction to give the right care to the right people. How on earth do you apply that philosophy

[00:41:41] to the GLP-1 weight loss drugs we talked about earlier? The million-dollar question. Everyone wants them, and they bankrupt the company. That brings us to step three, structured GLP-1 access. You don't have to choose between going bankrupt or banning the drug. This is where theory meets reality. What's super contrast the two divergent paths employers are taking right now? On one side, you have the outright bans. We discussed the University of Missouri, which calculated that keeping GLP-1 coverage

[00:42:08] would trigger an apocalyptic 28% premium hike for every single employee. Which they just couldn't do. The state of North Carolina, the state of West Virginia, Cigna's own internal employee plan, HCA Healthcare, they all looked at the math and dropped weight loss coverage completely. It's the nuclear option. But on the other side, we have organizations attempting to thread the needle with structured access. Tell us about the Jefferson Health approach. Jefferson Health is a massive organization with roughly 65,000 employees. They refused to ban the drugs,

[00:42:37] but they also refused to just hand out blank checks. Right. Instead, they implemented a strict requirement. Any employee seeking GLP-1 coverage was mandated to actively participate in a comprehensive, ongoing diet and lifestyle telehealth program. So you can't just get it and walk away. You cannot just ask your doctor for a prescription, get the drug, and walk away. Clinicians closely guide the titration of the dosing. And registered dietitians work directly with the patients to aggressively manage side effects

[00:43:06] and build sustainable nutritional habits. Isn't requiring an employee to go to a company-mandated dietitian just a polite way of creating bureaucratic hoops to jump through so fewer people take the expensive drug? A friction point designed to be so annoying that half the employees just give up. A degree of cynicism is definitely warranted whenever an employer adds a step to access care. Adding friction naturally reduces utilization, but from a purely clinical perspective, the friction in this specific case

[00:43:35] is medically essential. How so? These are profoundly powerful endocrine drugs. They carry significant, sometimes debilitating side effects, severe gastrointestinal distress, rapid muscle loss if protein intake isn't monitored. A specialized dietitian isn't a bureaucratic hoop. They are a necessary component of the medical treatment protocol. And what were the financial and clinical results for Jefferson Health? They reported saving an estimated $20 million

[00:44:02] while simultaneously maintaining a 90% persistence and retention rate for the employees in the program. That's incredible. The state of Connecticut faced a similar crisis and adopted a similar solution. Connecticut saw their state GLP-1 costs explode from roughly $8 million in 2020 to a staggering projected $40 million in 2024. They implemented a mandated telehealth lifestyle program to rein in the waste and ensure the drugs were generating actual health outcomes.

[00:44:31] Because simply writing a check for Wegovy isn't healthcare, it's just a transaction. The drug requires behavioral scaffolding to actually work long-term. Behavioral scaffolding is exactly what it is. If we connect this to the bigger picture, the clinical reality of these drugs is incredibly unforgiving. The Step 1 trial extension data revealed that if a patient simply stops taking the GLP-1 medication without having built a foundational architecture of lifestyle changes, they regain two-thirds of the lost weight within a single year. Wow.

[00:45:00] Two-thirds. Furthermore, real-world claims data from Prime Therapeutics showed that patient persistence is abysmal. Only 1 in 12 patients actually remain on the therapy after three years. So if you just hand out the drug without the scaffolding, you are throwing tens of thousands of dollars down the drain on an employee who is going to quit the drug in three months because they feel nauseous, and then they will immediately regain all the weight anyway. It's the worst of both worlds. Precisely. Structured access eliminates that clinical waste.

[00:45:29] It ensures the corporate investment is actually generating a permanent health outcome. And Westover emphasizes that leaders need to remember how rapidly this specific pharmaceutical market is evolving. The prices are going to change. Banning the drugs entirely today is incredibly short-sighted because the pricing dynamics are going to shift. Eli Lilly recently launched direct-to-employer pricing models at $449 a month for ZepBound. And new oral alternatives are entering the pipeline

[00:45:58] at around $149 a month. The market will correct, and employers need a structure ready to handle it. We have managed the pharmacy side of the crisis, but now we have to manage the hospital side. Step four of the playbook is steering to high-quality care. The strategy here is moving beyond passive networks and actively directing exactly where employees go for major complex procedures. The primary case study for this is Walmart. And Walmart is an unparalleled case study because of their sheer massive scale.

[00:46:27] So in 2013, they launched what's known as the Centers of Excellence Program, which in 2014, they kind of aggressively expanded to cover major joint replacements, and those specifically being like hips and knees. Picture a Walmart associate working in a store in rural Ohio. Their local doctor says they need a knee replacement. Instead of just letting them go to the community hospital down the street, what did Walmart do? Walmart's benefits team identified a select network of the absolute top-tier,

[00:46:57] world-class orthopedic facilities across the country, and they communicated a radical proposition to their associates. If you need a new knee, we will fly you across the country to this specific elite center of excellence. Wait, fly them across the country? Yes. We will cover all of your travel logistics, we will pay for your hotel, and your actual surgery will be completely 100% free. Zero copay, zero deductible. On the surface, flying an associate across the country for a surgery sounds like

[00:47:26] an absurdly expensive perk. Why would a company focusing on the bottom line offer that? Because of the massive cost savings generated by world-class quality. When these associates arrived at the centers of excellence, the world-class experts rigorously evaluated them before ever opening an operating room. They discovered a truly shocking statistic. What was it? Experts determined that 20% of the Walmart associates, who had been explicitly told by their local doctors that they urgently needed a joint replacement,

[00:47:56] did not actually need the surgery. One in five people were about to be put under anesthesia and have their bodies permanently altered for a surgery they didn't even need. Yes. And avoiding a $30,000 unnecessary surgery pays for a phenomenal amount of plane tickets and hotels. I bet. But even for the 80% of associates who did require the surgery, the financial outcomes were incredible. The cost per case was 15% lower at the center of excellence, averaging $23,500

[00:48:25] compared to $27,700 locally. Lower cost and better quality. Furthermore, the hospital stays were shorter and the associates were 70% less likely to be readmitted to the hospital for post-surgical complications. It is an astonishing win-win. The employee gets vastly superior care without paying a dime and the company saves money. But Walmart didn't just use a carrot forever, right? They eventually brought out a pretty heavy stick. They did. In 2018,

[00:48:55] when the program was thoroughly proven, highly rated by employees and well-established, Walmart introduced a penalty. If an associate chose to ignore the center of excellence option and stubbornly went to a local out-of-network hospital for the surgery anyway, they faced a massive 50% copayment penalty. So if I'm understanding this, it's like having a highly trusted elite mechanic who tells you, hey, you just need a new timing belt. You don't need us to replace the entire engine.

[00:49:26] You save money and your car runs perfectly. But the friction here is human nature. How do employees feel about their boss telling them which doctor to use? It can absolutely cause cultural friction if it is not communicated brilliantly. But this program highlights crucial counterintuitive reality in American health care. Price and quality often have absolutely zero correlation. A more expensive hospital is not necessarily a better hospital. That's so counterintuitive.

[00:49:54] In fact, specialty hospitals that perform thousands of knee replacements every single year are often significantly cheaper and have drastically lower complication rates than a general local hospital that only performs 10 a year. Practice makes perfect. But the key distinction Westover points out is that steering only works if the penalty is paired with immense, frictionless support. Absolutely. You cannot just build a narrow, restrictive network and aggressively punish people for going outside of it. If you want people to utilize the center of excellence,

[00:50:24] you have to make the high-value path the undeniably easy path. Right. You handle all the daunting travel logistics. You waive the co-pays completely. You provide a concierge nurse navigator to hold their hand through the process. If you just add 50% penalties without providing world-class support, you will breed massive resentment. Which flows perfectly into the final step of the playbook, step five, candor and insurance literacy. Because none of these brilliant structural changes,

[00:50:53] not the value-based co-pays, not the centers of excellence, not the GLP-1 telehealth mandates, none of it matters if the employee feels ambushed by confusing paperwork. The communication strategy is arguably the most neglected, underfunded component of benefit design. The Westover paper cites deeply concerning behavioral economics research by George Lowenstein from 2013, which empirically proved that American consumers fundamentally do not understand health insurance. We really don't. They cannot correctly answer basic multiple-choice questions

[00:51:23] about how deductibles, co-insurance, or maximum out-of-pockets actually work. It is an entirely different language. It's almost designed to be opaque. It is. A subsequent study by Sara Bhargava in 2017 illuminated the devastating financial consequences of that confusion. Bhargava found that employees routinely select what economists call financially dominated plans. Financially dominated. What does that mean? This means when an employee is presented with a menu of options,

[00:51:53] they are so overwhelmed and confused that they actively select a plan that is mathematically guaranteed to cost them more money than another option on the exact same menu for the exact same network coverage. They pick the absolute worst plan out of pure anxiety and decision fatigue. Exactly. So when an employer is forced to make a difficult structural change, they must communicate it with extreme, almost uncomfortable candor. Like the Missouri example. Take the University of Missouri's decision to cut GLP-1 coverage.

[00:52:23] We might strongly disagree with the clinical wisdom of dropping the benefit, but we must praise their communication strategy. They didn't bury the cut in a footnote on page 40 of a PDF. Right. They came out and explicitly told their workforce, look at the math. If we keep this benefit, every single employee's premium will go up by 28% this year. We cannot afford to do that to our lower wage workers, so we have to cut it. They treated their employees like adults and showed them the actual math.

[00:52:53] They showed the math. It loops entirely back to Colquitt's theory of organizational justice. Even if an employee loses a benefit they desperately wanted, clearly explaining the why preserves the psychological contract. If an HR department tries to spin a benefit cut as an enhancement, using slick marketing jargon, they destroy their credibility instantly. Employees are not stupid. They know exactly when a takeaway is being spun as a positive. Precisely. The paper strongly advocates for the creation

[00:53:22] of benefits advisory councils. This means actually bringing a diverse cross-section of employees into the boardroom months before open enrollment begins. You explain the raw cost pressures to them and you ask for their input on the agonizing trade-offs. Put it to the team. If the company is facing a million-dollar deficit, ask the council, would you rather we raise deductibles across the board or would you rather we narrow the hospital network to exclude the most expensive facility?

[00:53:52] Give the workforce a genuine voice in the architecture of their own safety net. So, what does this all mean? We just need HR to stop acting like marketing executives and start acting like math teachers. That's a great way to put it. Honestly, yes. Okay, we are entering the final stretch of this deep dive. We've covered the entire five-step playbook. Let's pull all these specific tactical maneuvers together into a unified philosophy for the future of work. Section 11 of the Westover paper

[00:54:21] outlines the long-term vision, framing health as a core workforce capability. The overarching thesis of Westover's conclusion is that corporate America must stop thinking in 12-month reactive renewal cycles. Constantly putting out fires. The annual panicked scramble in August to shave 2% off the premium increase before open enrollment is a losing game. Organizations need to build multi-year strategic roadmaps with explicit, unmovable affordability metrics.

[00:54:51] What exactly does an explicit affordability metric look like in practice? It looks like a board-level written commitment stating, we will never allow the premium contribution for our lowest paid quartile of workers to exceed 5% of their gross salary. Oh, that's a hard line in the sand. Once leadership makes that hard commitment, it forces the entire organization to adopt the difficult structural changes we've discussed, like reference-based pricing or centers of excellence. They have to do the hard work

[00:55:21] because they have voluntarily removed the lazy lever of simply cost-shifting the deficit onto the frontline workers. The paper also takes a pretty hard evidence-based swing at the traditional corporate wellness programs that we've all been forced to participate in, doesn't it? It does. And the empirical data thoroughly supports the critique. The paper cites rigorous large-scale studies, specifically the BJ's Wholesale Club trial and the massive Illinois Workplace Wellness Study conducted by Jones and the work

[00:55:50] by Song and Baker. They rigorously analyze classic corporate wellness programs. You mean the step counting challenges, the biometric health risk assessments, the subsidized meditation apps? Yes. The stuff that always feels a little bit like corporate window dressing to make the company look like they care? Exactly. And the studies conclusively found that these generic programs have almost zero effect on actual clinical outcomes or overall health care spending in the short run. Wait, really? Mm-hmm.

[00:56:19] If people are participating in a step challenge and walking more, shouldn't overall health care costs logically go down? They would if the right people were participating. The failure of these programs is driven entirely by self-selection bias. The employees who eagerly sign up for the corporate step challenge are the marathon runners, the cyclists, the people who already go to the gym five days a week. The employees who are actually driving the catastrophic health care costs, the individuals struggling with unmanaged complex

[00:56:49] diabetes, severe clinical depression, or chronic joint pain, they do not sign up for a competitive step challenge. So the company is spending millions of dollars to financially reward the already healthy people for being healthy while completely ignoring the sick people who actually need clinical interventions? Right. Instead of wasting capital on generic wellness programs, organizations need to invest heavily in robust primary care, targeted chronic condition management, and data-driven clinical insights.

[00:57:19] That makes so much more sense. The ultimate paradigm shift is moving away from viewing health benefits as a frustrating, escalating line item expense on the P&L, and moving toward viewing health as a core strategic workforce capability. If you want a highly productive, innovative, resilient organization, you physically need healthy human beings to operate it. It's the difference between buying your employees a meditation app subscription they'll never use versus actually making sure their insulin

[00:57:48] doesn't bankrupt them. One is a superficial perk. The other is a literal lifeline. And providing a lifeline is how you build deep institutional loyalty that outlasts any single paycheck or standard retention bonus. What an incredible journey through the data today. Let's do a quick synthesis of everything we've covered. We started with the harsh $28,000 reality of the family premium, driven largely by unchecked regional hospital monopolies and devastating specialty drug costs.

[00:58:18] Mm-hmm. We navigated the incredibly complex, politically charged GLP-1 tension, balancing the promise of a cardiovascular miracle cure with the threat of immediate corporate bankruptcy. We saw how the default strategy of just shifting costs to employees backfires spectacularly, causing people to skip vital care, stagnating wages, and destroying company culture. We covered a lot of ground. We really did. And then we laid out the five-step evidence-based playbook, demanding

[00:58:47] ruthless purchasing discipline like Montana State, adopting value-based design like Aetna to eliminate co-pays for vital care, creating structured dietician-led access for weight loss drugs, aggressively steering care to elite centers of excellence like Walmart, and above all, communicating with brutal, transparent candor so employees aren't picking the worst plans out of fear. It is a formidable, deeply complex challenge. But the organizations that have the courage to embrace this playbook will not only control their

[00:59:17] escalating costs, they will fundamentally differentiate themselves in a highly competitive talent market. And that leads me to one final thought, something that wasn't directly printed in Westover's paper but has been bouncing around in my head this entire conversation when you mentioned job lock. Oh. If employer-sponsored insurance keeps tracking this exact way, if it keeps getting this complex, this astronomical expensive, and this deeply tied to massive corporate scale, what happens to the entrepreneurial spirit of America?

[00:59:46] That's a profound question. If leaving a massive corporate giant to start a small business means losing your access to the only affordable GLP-1 coverage or losing your ability to access that life-saving center of excellence surgery, do we accidentally create a future where the best, most innovative talent is permanently trapped in Fortune 500 cubicles simply to stay alive? Wow. It's a chilling thought, and it's something to really mull over the next time you are sitting at your desk,

[01:00:15] staring at that packet, and checking that open enrollment box. Thank you so much for joining us for this deep dive. Keep asking questions, keep looking past the surface, and we will catch you next time.